Abstract
Lung cancer continues to be the leading cause of cancer-related mortality in the United States. Brain metastases are a significant problem in patients with lung cancer and have conventionally been treated with whole-brain radiation. This article reviews the data for systemic chemotherapy to treat brain metastasis from lung cancer and examines the activity of small molecule tyrosine kinase inhibitors for the targeted therapy for brain metastases from EGFR-mutant and ALK-rearranged non–small cell lung cancer. Future directions for evaluating the role of immunotherapy in treating brain metastasis are also discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 157-176 |
| Number of pages | 20 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 31 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 1 2017 |
Keywords
- Brain metastases
- Chemotherapy
- Immunotherapy
- Lung cancer
- Targeted therapy